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Collagen makes up a large proportion of the human body, particularly the 
skin. As the body ages, collagen content decreases, resulting in wrinkled skin 
and decreased wound healing capabilities. This paper presents a method of 
delivering type I collagen into porcine and human skin utilizing a 
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polyvinylpyrrolidone microneedle delivery system. The microneedle patches 
were made with concentrations of 1, 2, 4, and 8% type I collagen (w/w). 
Microneedle structures and the distribution of collagen were characterized 
using scanning electron microscopy and confocal microscopy. Patches were 
then applied on the porcine and human skin, and their effectiveness was 
examined using fluorescence microscopy. The results illustrate that this 
microneedle delivery system is effective in delivering collagen I into the 
epidermis and dermis of porcine and human skin. Since the technique 
presented in this paper is quick, safe, effective and easy, it can be considered 
as a new collagen delivery method for cosmetic and therapeutic applications. 
 
Keywords: Collagen, Microneedles, Biomaterials, Transdermal delivery 
 
Abbreviations 
CD Circular dichroism 
C1 Type-I collagen 
DAPI 4′,6-Diamidino-2-phenylindole 
MES Morpholino ethanesulfonic acid 
MMP-1 Matrix metallopeptidase 1 
MWCO Molecular weight cut off 
OCT Optimum cutting temperature 
PDMS Polydimethylsiloxane 
PEG Polyethylene glycol 
PVP Polyvinylpyrrolidone 
RBITC Rhodamine B isothiocyanate 




The human body is composed of 20% proteins by mass, 
and 25–35% of total protein is represented by collagen, of which 
roughly 90% is type I collagen (C1).7 C1 contributes to the make-up of 
many types of tissue within the human body, including skin, tendon, 
teeth, bone, and endothelial lining. Deficits of C1 can lead to numerous 
negative outcomes, from cosmetic blemishes such as wrinkles and 
decreased ability of wound healing, to life altering and debilitating 
diseases, such as Osteogenesis Imperfecta and Ehler–Danlos 
Syndrome.6,23,33 These deficits can be caused by congenital defects, 
infection, autoimmune diseases, nutrient deficiency, sun damage, or 
old age.4,20,26 Aging alone can reduce the collagen content of adult 
human skin to 1% per unit area per year.27 This decrease is due in 
large part to the formation of free radicals, which accelerate enzymatic 
degradation of the dermal layers and inhibit synthesis of collagen 
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fibers. Increased iron levels have been shown to increase the 
sensitivity of fibroblasts and keratinocytes to UVA light, leading to 
upregulation of matrix metallopeptidase 1 and playing a major role in 
skin photoaging, especially among post-menopausal women.14 
Different approaches have been employed to introduce C1 into 
the skin to treat cosmetic blemishes and contribute in the wound 
repair process. Commonly, cosmetic collagen introduction has been 
performed using syringe injections; whereas collagen based bandages 
have been utilized to assist in wound healing3,9,25 Though these 
methods have proven to be effective, they include many drawbacks. 
The use of syringes is accompanied by the risk of an accidental 
stabbing which may result in injury that is highly destructive to facial 
tissue. This could negate the commercial benefit of injecting collagen 
into sensitive areas such as lips and lines around the mouth. 
Additionally, a syringe can only introduce C1 into the skin in large 
scale and globular forms, which does not always provide the adequate 
distribution of collagen necessary for homogenous skin plumpness and 
wrinkle repair. On the other hand, though collagen bandages have 
been shown to increase fibroblast recruitment to trauma areas, they 
can only be applied superficially, restricting their effectiveness. 
Various techniques of microneedle delivery have been created 
utilizing solid, hollow, and dissolvable tips.17 Microneedles have 
illustrated their ability to transdermally (and ocularly) deliver various 
molecules in a targeted manner using injectable, drug coated metal or 
polymer microneedles.1,10,13,19,22 Metal microneedles rollers 
(Dermaroller) have been shown to induce C1 deposition in Murine 
skin.16 However, there has been no attempt made for the use of 
microneedles as a delivery system for C1 into human skin. We have 
previously demonstrated the delivering of allergen molecules into 
human foreskin.30 In the present study, we prepared a dissolvable 
polymeric microneedle for transdermal delivery of C1. 
A dissolvable C1 microneedle delivery system is superior to the 
use of syringes or bandages for both cosmetic and wound treatment 
purposes. Dissolvable microneedles can eliminate the danger of sharps 
that is present when using syringes. This would make C1 application 
simpler and easier, allowing for self-application within one’s own 
home, which could open up a potentially lucrative market for at-home 
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C1 delivery. Moreover, a microneedle delivery system would allow 
even distribution of C1 throughout the application zone, eliminating 
the threat of globular distribution. This effectively contributes to an 
even and natural look to the skin, instead of the bulbous look that may 
result from syringe injections. 
In addition to the increased cosmetic benefits, the use of a 
microneedle delivery system would greatly benefit the wound healing 
process. Dissolvable microneedles can penetrate into the skin 
perpendicularly, instead of parallel administration of collagen in 
bandages. Such intradermal perpendicular scaffolding has been shown 
to increase the rate of wound healing in which fibroblasts are 
recruited, helping to rapidly heal trauma to the skin.15 In the present 
study, we have utilized porcine skin, a well-accepted adult human skin 
analogue, and human foreskin to illustrate the effectiveness of 
employing polyvinylpyrrolidone microneedles for transdermal delivery 
of C1. 
Materials and Methods 
Preparation of PDMS Negative Mold 
PDMS molds were fabricated as reported previously.30 In short, 
a silicon wafer (1 mm thick, 100 mm in diameter) with oxide mask 
was patterned using standard contact lithographic techniques with 
thick photoresist and subjected to deep reactive ion etching. The 
residual photoresist was removed using oxygen plasma and the wafers 
were washed in sulfuric acid. The silicon wafer was diced 
into ~0.6 × 0.6 cm squares with 12 × 12, 12 × 6 or 6 × 6 needle 
arrays. To facilitate easy removal of molded materials, all wafers were 
silanized overnight in a vacuum chamber prior to use. To prepare 
PDMS mold, dimethylsiloxane monomer and curing agent (10:1 w/w, 
Dow Corning, Midland, MI) were mixed and poured onto silicon 
positive mold in a sterile Petri dish. To remove bubbles of trapped air, 
a vacuum was applied for 5 min. To cure the PDMS, the Petri dish was 
incubated at 37 °C overnight. 
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Labeling of Collagen I with Fluorophores 
C1 (~10 mg/mL) from rat tail tendon (Corning Inc, Cat# 
354249) was dialyzed against 50 mM MES buffer (pH 6.0). 25 µL of 
10 mg/mL rhodamine B isothiocyanate (RBITC) (Sigma-Aldrich Cat# 
283924) in DMF was diluted with 50 mM MES buffer (pH 6.0) to a total 
volume of 0.5 mL and added dropwise to 6 mL of 4 mg/mL C1 in 
50 mM MES buffer (pH 6.0). Reaction was kept at 4 °C for 4 h in the 
dark with stirring. Reaction mixture was then dialyzed at 4 °C in the 
dark against 50 mM MES buffer (pH 6.0) to remove unreacted RBITC. 
Preparation of Microneedle Patches 
Polyvinylpyrrolidone (PVP) (MW = 10 kDa) (Sigma-Aldrich, Cat# 
PVP10-500G) was dissolved in water to form solutions containing 
concentrations of 133.38, 266.76, and 533.52 mg/mL PVP. Poly 
ethylene glycol-400 (PEG) (Sigma-Aldrich, Cat# 202398), a plasticizer, 
was added to the PVP solutions in a ratio of 10 µL PEG/200 mg PVP. 
C1 was mixed with 50 mM MES buffer (pH 6.0) to create final solutions 
containing 10, 8, and 4 mg/mL C1. For the 1% C1 microneedle patch, 
370 µL of 133.38 mg/mL PVP/PEG solution was mixed with 125 µL of 
4 mg/mL C1 solution. For the 2% C1 microneedle patch, 367.4 µL of 
133.38 mg/mL PVP/PEG solution was mixed with 125 µL of 8 mg/mL 
C1 solution. For the 4% C1 microneedle patch, 179.98 µL of 
266.76 mg/mL PVP/PEG solution was mixed with 250 µL of 8 mg/mL 
C1 solution. For the 8% C1 patch, 86.2 µL of 533.52 mg/mL PVP/PEG 
solution was mixed with 400 µL of 10 mg/mL C1 solution. 1% 
rhodamine labeled C1 was used to prepare fluorescently labeled 1% 
C1 microneedle. For fluorescently labeled 2, 4, 8% C1 microneedles, 
1% rhodamine labeled C1 was mixed with unlabeled C1 to reach the 
final concentrations. 
PVP/C1 solutions (50 µL) were then pipetted onto PMDS mold 
(~0.6 cm × 0.6 cm). The mold was placed in a vacuum to force the 
liquid into the needle chambers. Air bubbles were removed using a 
pipette tip. After the solution was allowed to air dry for 4–5 h, another 
50 µL of PVP/C1 solution was added. The solution on the mold was 
allowed to dry overnight before addition of the final 70 µL of PVP/C1 
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solution. After drying, the microneedle patches were then peeled from 
the mold using an adhesive tape. 
Characterization by Scanning Electron Microscopy 
(SEM) and Confocal Fluorescence Microscopy 
Microneedle morphology was examined by scanning electron 
microscopy (SEM). The microneedles along with their bases were 
attached to an SEM sample stub using a double-stick carbon tab. The 
samples were coated with a 7 nm thick gold–palladium layer using a 
Denton Desk II vacuum sputter coater. Imaging was carried out on a 
Hitachi S-3400 N VP scanning electron microscope at the Cell Sciences 
Imaging Facility, Stanford University. C1 distribution inside the 
microneedles was examined by confocal fluorescence microscopy. 
Rhodamine labeled 1% C1 microneedles were secured in embedding 
resin and imaged by Leica SP5 upright confocal fluorescence 
microscope. 
Electron Beam (e-beam) Sterilization 
100 µL of ~10 mg/mL naked C1 in 50 mM MES buffer (pH 6.0) 
was air dried at room temperature. Naked C1 and C1 microneedles 
were placed in a sealed plastic bag containing desiccant and shipped at 
ambient temperature to Nutek Corporation (Hayward, CA) for e-beam 
treatment. A split dose of 12.5 + 12.5 kGy was used with sample 
freezing before, between and after passes. 
SDS-PAGE Analysis of Collagen 
The collagen microneedles treated or untreated with e-beam 
were dissolved in excess 50 mM MES buffer (pH 6.0) and washed three 
times with MES buffer using a 30,000 MWCO Vivaspin 20 filter 
(Sartorius) in a refrigerated centrifuge to remove PVP. To completely 
solubilize collagen, the washing was continued for additional three 
times using 0.02 N acetic acid. Air dried naked C1, treated or 
untreated with e-beam were redissolved in 0.02 N acetic acid. C1 
concentration was determined using the Pierce BCA protein assay 
(Thermo Scientific Cat# 23227) with the original C1 in 0.02 N acetic 
acid (Corning Inc, Cat# 354249) as calibration standard. We typically 
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recover >95% of the input. 1.5 µg of collagen in LDS sample buffer 
(Life Technologies) with reducing agent was loaded onto a NuPAGE 4–
12% bis tris gel (Life Technologies). After electrophoresis, the gel was 
washed in distilled water and stained with SimplyBlue SafeStain (Life 
Technologies). 
Enzyme-Linked Immunosorbent assay (ELISA) to 
Determine Concentration of Functional Collagen 
Naked C1 and C1 in microneedles were recovered as described 
above. Rat Type I Collagen Detection Kit (Chondrex Inc, Cat# 6013) 
was used to determine the concentration of functional C1. All samples 
were diluted to 2 µg/mL using the Sample/Standard Dilution Buffer 
(Solution B) provided in the kit. ELISA was performed according to 
manufacturer’s instruction. For each condition, three samples were 
tested with assay duplicate for each sample. 
Circular Dichroism (CD) Spectra of Collagen Recovered 
from Microneedles 
Naked C1 and C1 in microneedles were recovered as described 
in the SDS-PAGE experiment. The collagen solution was diluted in 
0.02 N acetic acid to 0.1 mg/mL and placed into a 0.1 cm path length 
quartz cell. Spectra were acquired using a Jasco Model J-810 
spectropolarimeter (Jasco, Japan) from ≈190 to 260 nm with a scan 
rate of 100 nm/min. The CD data represent averages from five 
recordings and was processed for routine baseline correction and 
subtraction of buffer spectra according to the manufacturer’s 
instructions. For samples that had traces of PVP, high photomultiplier 
voltage at low wavelength precluded data acquisition to wavelengths 
as low as 190 nm. 
Porcine Skin Penetration and Microscopic Examination 
of Fluorescence 
Cadaver porcine skin was obtained from euthanized pigs that 
had been used in previous cardiac experiments at Stanford. The skin 
was collected after the pig had been euthanized according to the 
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approved Stanford Administrative Panel on Laboratory Animal Care 
guidelines. Porcine skin was cut into a ~2 cm × 2 cm square and 
placed on a piece of glass with epidermis facing up. A small patch of 
fluorescently labeled C1 microneedle patch (~0.6 cm × 0.6 cm) was 
applied onto the skin and secured in place with a Tegaderm dressing 
(3 M). The microneedle patch was pressed down using a small Petri 
dish for 30 s. After 15 min, the Tegaderm was removed and the skin 
was gently stripped with another clean Tegaderm to remove any 
residue on the surface. For low magnification fluorescent needle 
marker imaging, the skin was imaged using a fluorescence 
stereomicroscope (Leica M165 FC with DSR filter). For Trypan blue 
staining, Trypan blue was applied to skin surface and incubated for 
1 min. After gentle washing of the skin surface, pictures were taken 
using a stereomicroscope (Leica M165 FC). For fluorescence imaging of 
skin sections, the skin was immersed in 4% paraformaldehyde and 
fixed overnight. Fixed skin was embedded in optimum cutting 
temperature (OCT) compound (Fisher HealthCare) on dry ice and 
cryosectioned. Tissue slides were preserved in mounting medium with 
DAPI (4′,6-diamidino-2-phenylindole) (Vector Labs) and examined 
with fluorescence microscopy. 
Foreskin Penetration and Microscopic Examination of 
Fluorescence 
Human foreskin was obtained from discarded neonatal foreskins 
obtained after elective circumcision. Institutional Review Board 
approval was obtained prior to tissue collection. The sample was cut 
into a ~2 cm × 2 cm square, stretched and pinned onto a Styrofoam 
board with epidermis facing up. A small patch of fluorescently labeled 
1% collagen microneedle patch (~0.6 cm × 0.6 cm 12 × 12 array) 
was applied onto the skin and secured in place with a Tegaderm 
dressing. The microneedle patch was pressed down using a small Petri 
dish for 30 s. After 15 min, the Tegaderm was removed and the skin 
was gently stripped with another clean Tegaderm to remove any 
residue on the surface. Still pinned on the styrofoam, the skin was 
immersed in 4% paraformaldehyde and fixed overnight. Fixed skin was 
embedded in OCT compound on dry ice and cryosectioned. For laminin 
332 immunofluorescence staining, a rabbit polyclonal antibody to 
laminin 332 (pKaL) from Marinkovich lab (Stanford University) was 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Annals of Biomedical Engineering, Vol 43, No. 12 December 2015): pg. 2978-2990. DOI. This article is © Biomedical 
Engineering Society and permission has been granted for this version to appear in e-Publications@Marquette. Biomedical 
Engineering Society does not grant permission for this article to be further copied/distributed or hosted elsewhere 
without the express permission from Biomedical Engineering Society. 
10 
 
used at 1:400 dilution. Goat anti-rabbit IgG Alexa Fluor 488 secondary 
antibody (Life Technologies) was used at 1:500 dilution. Tissue slides 
were preserved in mounting medium with DAPI and observed using a 
fluorescence microscopy. 
Results 
Characterization of Microneedles 
Bright field imaging was used to illustrate the distribution of 
microneedles within the microneedle patch (Fig. 1a). A typical 
microneedle patch measures at 0.6 cm × 0.6 cm with an array of 
12 × 12 needles. The microneedles were spaced about 500 µm apart, 
with each needle measuring approximately 365 µm in height and 
135 µm in diameter at the base (Fig. 1b). The microneedles are 
tapered at the tips. This is consistent with the dimension of the silicon 
positive mold used to manufacture the polymer microneedles (Fig. 1c). 
The microneedle patches with 1, 2, 4, 8% (w/w) of C1 were prepared 
and inspected using SEM to study the morphology and surface 
characteristics (Fig. 2). A similar rough surface feature was observed 
for 1, 2, 4% C1 microneedles. This pattern was formed by replicating 
the surface feature of the silicon positive mold as the same pattern 
was seen for the silicon microneedles (Fig. 2 top panels). At 8% C1, 
the surface displayed a slightly different fibrous feature, possibly due 
to the formation of more fibrous aggregates by higher concentrations 
of collagen. Regardless of the collagen concentrations, the microneedle 
surface became smoothened after extended exposure in the air (1 h) 
(Supplementary Figure S1). This is mainly due to the hygroscopic 
property of PVP. For this reason, all the microneedle patches were 
stored in vacuum or with desiccant. However, within 1 h, the needles 
remained sharp (Supplementary Figure S1) which allows enough time 
to perform the different experimental procedures. At higher 
concentrations of C1, we also found more defective microneedles 
(Supplementary Figure S1 8%), indicating higher concentration of 
collagen may affect the mechanical strength of the microneedles. 
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Figure 1. (a) Bright field image of microneedles patch showing array of microneedles. 
(b) Bright field image illustrating the dimensions of a single needle within the 
microneedle patch. (c) SEM images of the silicon positive mold used to make PDMS 
negative mold. 
 
Figure 2. SEM images of silicon needle and PVP-C1 microneedles with different C1 
content, 1, 2, 4, 8% C1/PVP (w/w). The cracking was likely caused by the coating 
process performed in the vacuum sputter coater before SEM images were taken. 
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To study the distribution of C1 inside the microneedles, 
microneedles with fluorescently labeled C1 (1%) were embedded in a 
resin block and imaged by confocal fluorescence microscopy. Optical 
sections of individual microneedles showed that C1 were uniformly 
distributed across the horizontal plane (Fig. 3). Vertical sections of the 
needles indicated that C1 were slightly more concentrated toward the 
tips of the needles, possibly due to aggregation at the tips. 
 
Figure 3. (a) Scheme showing the embedding of microneedles in resin and imaging. 
(b) Confocal images of two rhodamine labeled PVP-C1 microneedles at x, y and z 
optical sections. 
Stability of C1 in Microneedle Patches After Electron 
Beam Sterilization 
For C1 microneedle to be considered for potential commercial 
use, a proper sterilization procedure needs to be studied. With faster 
turnaround, less material degradation and lower cost compared to 
gamma irradiation, electron beam sterilization (e-beam) has become a 
commercially proven procedure for sterilizing a wide variety of medical 
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products. We therefore chose e-beam technology to sterilize C1 
microneedle. As control, naked C1 in 50 mM MES buffer (pH 6.0) was 
air dried at room temperature. After e-beam treatment, naked C1 was 
redissolved and C1 in microneedles were recovered as described in the 
Method section. The stability of C1 was first checked with protein gel 
electrophoresis. As shown in Fig. 4(a), no degradation was observed 
when C1 was air dried or recovered from microneedles without e-beam 
treatment. Some degradation was observed when C1 was treated with 
e-beam. Densitometry of the gel image indicated that after e-beam 
treatment, undegraded form of collagen reduced to 80.8 ± 2.1% 
(mean ± SD) compared to untreated control when C1 was 
incorporated in microneedles. However, ~38% of naked C1 protein 
(compared to untreated control) was degraded after e-beam 
treatment, indicating that collagen was protected in the microneedle 
from the damage caused by e-beam. The major bands representing 
the monomer α1 (I) and α2 (I) can be observed for all the samples. 
There is also no increase of the dimeric (β) or oligomeric from of C1 
after e-beam treatment, indicating no additional crosslinking was 
caused by e-beam treatment. We confirmed the structural integrity of 
recovered C1 using circular dichroism (CD) spectroscopy which is an 
excellent technique to determine the conformation of proteins and 
peptides in solution.12 The CD spectrum of the untreated native C1 
showed a signature positive peak at 222 nm and a signature negative 
peak at ≈198 nm (Fig. 4c). These peaks were diminished when C1 was 
denatured by heating (Fig. 4c). When air dried naked C1 was treated 
by e-beam, a small decrease of the two peaks were observed 
indicating a partial loss of the triple-helical structure (Fig. 4d). C1 
recovered from the microneedle without e-beam treatment showed 
similar CD spectra compared to untreated control indicating that C1 
retained its native triple-helical conformation in PVP microneedles 
(Fig. 4e). After e-beam treatment, C1 recovered from the microneedle 
maintained the overall spectra, but also showed a partial loss of the 
triple-helical structure, especially at lower percentage of C1 (Fig. 4f). 
To test whether C1 recovered from microneedle maintained its 
function with or without e-beam treatment, an ELISA specific to rat 
type I collagen was performed. Prior to ELISA experiment, C1 
concentration was determined using a BCA protein assay with the 
original C1 in 0.02 N acetic acid as calibration standard. Naked C1 and 
C1 recovered from microneedles were diluted to 2 µg/mL for the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Annals of Biomedical Engineering, Vol 43, No. 12 December 2015): pg. 2978-2990. DOI. This article is © Biomedical 
Engineering Society and permission has been granted for this version to appear in e-Publications@Marquette. Biomedical 
Engineering Society does not grant permission for this article to be further copied/distributed or hosted elsewhere 
without the express permission from Biomedical Engineering Society. 
14 
 
ELISA. Because the standard collagen solution provided in the ELISA 
kit was from a different source, the overall concentrations determined 
by the ELISA were higher than the value determined by the BCA 
assay. For this reason, the concentrations of functional collagen of all 
the samples were compared to the level of untreated control and the 
results were expressed as percent functional collagen. After heating 
the collagen at 90 °C for 5 min, no functional collagen could be 
detected, confirming the specificity of the assay (data not shown). As 
shown in Fig. 4(b), for C1 recovered from microneedles, ~80–90% of 
protein remained active. After e-beam treatment, there is a small 
decrease of functional collagen concentration compared to no e-beam 
treatment at 1, 2, 4% C1 (not statistically significant). In contrast, for 
air dried naked collagen, a more significant loss of function was 
observed. After e-beam treatment, only 64% of naked collagen 
remained active (P < 0.05 when compared to all other samples except 
for naked C1 without e-beam which is not significant). This result is 
consistent with the SDS-PAGE and CD results and further confirms that 
more than 80% of C1 remained stable and functional in the 
microneedle and the incorporation protected C1 from the damage 
caused by e-beam. 
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Figure 4. (a) SDS PAGE showing naked C1 and C1 recovered from PVP-C1 
microneedles patch made with 1, 2, 4, 8% C1 (w/w) with and without e-beam 
treatment. Control is untreated collagen in 50 mM MES buffer (pH 6.0). (b) 
Concentrations of functional collagen were determined by rat type I collagen specific 
ELISA. Results are presented as % functional collagen compared to untreated controls 
(mean ± SD, n = 3). (c) CD spectra of C1 as controls, native conformation at 4 °C and 
denatured at 60 °C. (d) CD spectra of untreated control, air dried naked C1 with and 
without e-beam treatment. (e) CD spectra of C1 recovered from 1, 2, 4, 8% 
microneedles after preparation without e-beam treatment. (f) CD spectra of C1 
recovered from 1, 2, 4, 8% microneedles that were subjected to e-beam sterilization. 
Porcine Skin Collagen I Application 
Porcine skin was used in vitro to test the penetrative and 
dissolvable properties of the microneedles due to its likeness to adult 
human skin.2,5,8 Dissolution kinetics of the microneedles (1% 
rhodamine labeled C1) were recorded by removing the microneedles 
from the skin at set intervals and imaging them utilizing a 
stereomicroscope (Fig. 5a). Dissolution of the microneedles could be 
observed as short as 15 s after insertion into porcine skin (Fig. 5a). 
More than 95% dissolution of the microneedles could be observed 
after 5 min (Fig. 5a). After 15 min of introduction to porcine skin, the 
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majority of the microneedle base was also dissolved (data not shown). 
The quick dissolving capability of these patches allow for rapid 
administration of C1 to the skin. Patches can be applied and held in 
place using the Tegaderm patch, and then removed after only a few 
minutes, making administration extremely fast and easy. 
 
Figure 5. (a) Images of PVP-C1 microneedles before and after 15 s, 1, 2 and 5 min, 
insertion into porcine skins. Lower panel shows quantification of needle heights at 
different time points. The heights of 15–20 needles were measured and the 
experiment were repeated three times. (b) Image of rhodamine labeled microneedles. 
(c) Fluorescent image of needle marks in porcine skin. (d) Needle marks on porcine 
skin after Trypan blue staining. 
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Fluorescent images were then taken of the needle marks on the 
porcine skins (Fig. 5c). Appearance of rhodamine fluorescence 
indicates that C1 was successfully implanted into the skin. The 
fluorescence pattern of rhodamine labeled C1 in skin is nearly identical 
to the original dimensions of the microneedle patch (Fig. 5b). Due to 
the elasticity of porcine skin, boundary displacement or tenting of the 
skin tissue occurs when microneedles are applied to it. Therefore in 
some area, the needles may not penetrate uniformly, and distances 
between penetration sites may not equate to distances between 
needles within the patch. Porcine skin penetration experiment was 
repeated with 1, 2, 4, 8% C1 microneedles to evaluate their 
penetration efficiency. All the microneedles contain 1% of rhodamine 
labeled C1. For 2, 4, 8% C1 microneedles, 1% labeled C1 was mixed 
with unlabeled C1 to reach the final concentrations. This enables 
comparison of penetration efficiency, not total protein delivery. Each 
distinct fluorescent needle mark is counted as a penetration site. The 
penetration efficiency was quantified as the number of needles 
penetrated/total number of needles (mean ± SD, n = 3) 
(Supplementary Fig S2). The penetration efficiency decreases as the 
percentage of collagen increases. An inspection of the microneedles 
under microscope revealed that increasing collagen content results in 
more defective needles. The collagen content may also affect the 
mechanical strength of the needles. Images showing the penetration 
pattern were also presented (Supplementary Fig S2). Although the 
penetration efficiency of 2% C1 microneedle is not statistically 
different from 1% C1 microneedle, we found the 1% needle gave more 
consistent and uniform delivery. It is possible that even with low 
penetration efficiency, higher percent C1 microneedles may achieve 
comparable or higher total protein delivery. However, uniform delivery 
is crucial in this application. Low penetration efficiency of higher 
percent C1 microneedle also means more loss of the collagen material, 
therefore driving up the cost. For these reasons, we decided to use 1% 
C1 microneedle for the rest of the study. 
Although the topical appearance of rhodamine indicates 
microneedle penetration, it is possible that the needles could just 
deform the skin, thereby creating a pocket without actually 
penetrating. To confirm penetration of the microneedles into the 
porcine skin, application sites were stained with Trypan Blue (Fig. 5d). 
Trypan blue stains damaged tissue and cells, indicating successful 
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penetration through the stratum corneum and into the epidermis. 
These results suggest that the microneedles are capable of 
successfully penetrating through the stratum corneum into the 
epidermis. 
Recent studies have shown that a greater spacing may prove to 
be optimal.18 To test the hypothesis that decreasing needle density will 
increase the force per needle resulting in more efficient or deeper 
penetration, we also prepared 12 × 6 and 6 × 6 patches (with all the 
microneedles distributed in the same 0.6 × 0.6 cm area) in addition to 
the 12 × 12 patch (Fig. 6b). To more accurately quantify the level of 
C1 delivery to various depths of the porcine skin, skin samples were 
embedded in OCT compound and sectioned into 25 µm sections 
parallel to the surface of the skin (Fig. 6a). Different compression and 
elastic properties within the porcine skin result in differential 
penetration for every needle. While some needles only penetrate a few 
tens of microns, some needles were capable of penetrating to 300 µm. 
When needle density decreased to 6 × 6, the total fluorescence at 
different depth decreased to ~1/2 but not 1/4 of the level achieved by 
12 × 12 patch, indicating protein delivery per needle is more efficient 
at 6 × 6 density (Fig. 6c). However, the same effect is not seen at 
12 × 6 density suggesting that the increment of force per needle at 
this density is not sufficient to affect needle penetration and protein 
delivery. 
 
Figure 6. Pig skin was punctured with PVP microneedle containing rhodamine labeled 
C1. Needle patch has standard size of 0.6 × 0.6 cm with 12 × 12, 12 × 6 and 6 × 6 
needle density. Cryosectioning was performed parallel to the surface. (a) 
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Representative fluorescent images for each 25 µm layers of porcine skin penetrated by 
a 12 × 12 microneedle patch. Scale bar = 500 µm. (b) Graphical representation of 
microneedle patches with different densities. (c) Total fluorescence was quantified for 
each 25 µm section and plotted against depth. 
Human Foreskin Collagen I Application 
The penetration of C1 (1% 12 × 12) microneedles with 
rhodamine labelled collagen to human foreskin was tested in a similar 
manner as can be found in Sun et al.30 Briefly, the foreskin was 
stretched and pinned to a piece of Styrofoam. The microneedles were 
attached to an adhesive bandage, and pressed onto the foreskin, 
where they were left to dissolve. The foreskin was then frozen in OCT 
Compound, cut into 10–25 µm sections, and stained for imaging. 
Fluorescence microscopy examination following application of a 
1% C1 microneedle patch illustrated a successful application. The 
epidermis can be identified as the dense layer of nuclei stained via 
DAPI. Invagination of the epidermis occurs at the points of contact 
with the microneedles, leading to compression. Red staining is 
indicative of the rhodamine labelled C1 that was delivered via the 
microneedle patches. Red staining within the nucleated areas of the 
section indicates that the microneedles were able to penetrate deep 
into the dermis. In fact, collagen was well established beyond a depth 
of 100 µm (Figs. 7a–7c). 
 
Figure 7. Fluorescent images of rhodamine labeled PVP-C1 penetrating human 
foreskins. Epidermis is on the left in (a, b, and c) Epidermis is on top in (d) Red, 
rhodamine fluorescence; blue, DAPI staining; green (panel d), laminin 332. 
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The area that connects the epidermis to the dermis is known as 
the basement membrane. The basement membrane is the border 
between the tightly packed epidermal keratinocytes and the much less 
densely crowded area of the papillary dermis. Many large proteins and 
peptides that can freely diffuse through the dermis are restricted from 
doing so in the epidermis due to the sheer density of cells as well as 
the presence of desmosomes. Thus, for the delivery of large molecules 
that target basal keratinocytes, the basement membrane, fibroblasts, 
or other sites in the lower epidermis or dermis, it is essential that the 
microneedles have the ability to penetrate all the way through to the 
dermis. Staining of the basement membrane laminin 332 reaffirms the 
ability of the microneedles to penetrate through the epidermal layer 
and deposit C1 well into the papillary dermal layer (Fig. 7d). 
The spacing of the invaginations within the epidermis can be 
seen in Fig. 7(c). This spacing is almost identical to the spacing seen 
on the microneedle patch prior to application. The pliability and 
movement of the skin during microneedle application make it 
impossible to have a completely uniform and evenly spaced C1 
delivery. However, the variation in microneedle penetration spacing is 
on the scale of tens of microns, resulting in much more evenly 
distributed C1 than would be obtained via an intradermal syringe 
injection. 
Red staining on top of the epidermis indicates that some 
rhodamine labelled C1 remained on the surface of the foreskin. This is 
most likely derived from the base part of the patch, and not from the 
microneedle portions themselves. It is possible to create microneedles 
that only contain the delivered molecule in the needle portion of the 
patch, and not in the base portion.29 However, many of the techniques 
used to do so involve using high temperatures or UV curation in the 
process. These conditions can cause the denaturation of many 
proteins, C1 included. We attempted to create microneedles that only 
contained C1 in the needles and not in the base at room temperature 
so as to avoid denaturing conditions. We first poured PVP with 1% C1 
into the needle portion of the mold and allowed it to dry. We then 
poured pure PVP solution over the needles and allowed that to dry to 
form the base. However, the pure PVP solution dissolved the 1% C1 
PVP in the needles, thus allowing the C1 to diffuse throughout the 
entire patch. Because of this, and due to the relatively low cost of C1, 
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we decided to use 1% C1 solution for the entire patch. For more 
precious cargo, alternative methods must be used. 
Discussion 
The results of our experiments illustrate the capability of our 
microneedle delivery systems to deposit C1 into porcine and human 
skin. Dissolution of the microneedles occurred within 5 min of 
application, and fluorescent imaging illustrated that the C1 was 
deposited deeply into the papillary dermis of the tissue. This shows the 
speed and effectiveness associated with microneedle application. 
For cosmetic collagen applications, the average cost in 2009 was 
between $480 and $510, without taking into account facility, 
medication, and anesthesia costs.31 Currently, techniques are being 
developed with which recombinant human collagen can be mass 
produced using tobacco plants.28 Combining mass produced collagen 
with a mass produced C1 microneedle delivery system distributed for 
at-home application could prove to be a very popular venture. 
Additionally, the use of C1 microneedles can significantly help 
reduce the time required in wound healing. Collagen serves as a 
substrate that promotes cellular proliferation and differentiation.25 
Instead of applying the collagen superficially as current bandages do, 
microneedles have the ability to apply collagen relatively deep into the 
dermis, which could serve to greatly aid in the recruitment of 
fibroblasts and keratinocytes, greatly expediting the healing process. 
In addition to cosmetic improvement and wound healing, 
microneedle based collagen delivery can provide other advantageous 
results. Collagen can serve to indirectly enhance the activity of 
monocyte-derived dendritic cells, thus helping to strengthen the 
human immune system.24 Implants of collagen VII may result in the 
healing of dystrophic epidermolysis bullosa, a disease which results 
from a lack of type VII collagen in the basement membrane.11,21,32 Our 
microneedles have shown their ability to deliver C1 up to and beyond 
the basement membrane zone. Thus, it is likely that microneedles 
containing type VII collagen will be able to do the same, healing one of 
pediatrics’ worst dermatological diseases. 
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The use of PVP microneedle delivery systems to transport C1 
into human skin is an easy, safe, and effective procedure, which may 
allow even distribution of C1 to the region of interest. C1 microneedles 
can be constructed in a short amount of time, and do not adversely 
affect the structure and function of the protein. Its benefits include 
cosmetic care, wound healing, and perhaps even enhanced immune-
capability and the cure of diseases such as dystrophic epidermolysis 
bullosa. The superior characteristics of this method of C1 delivery 
compared to the traditional techniques (e.g., injection), may open up a 
profitable market specifically in regard to the cosmetic applications in 
which the stress-free and at-home administration of C1 is important. 
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